AI For Pharma Growth

In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simona to explore how artificial intelligence is transforming drug discovery, R&D productivity, and enterprise strategy across the biopharma industry. Dr. Andre Bates shares a pragmatic view on AI in the biopharma industry, cutting through the hype to explore where AI is already delivering...

In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simona to explore how artificial intelligence is transforming drug discovery, R&D productivity, and enterprise strategy across the biopharma industry. Dr. Bates shares actionable insights into the real-world potential of AI to reduce time-to-market, cut development costs, and create competi...

In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simon for a deep dive into how AI is transforming the biopharma industry. With over two decades of experience applying AI across R&D, clinical development, regulatory, medical affairs, and commercial teams, Dr. Bates explains how the field has evolved from early digitisation to the current...

In this episode, we take you inside the AI factory — the place where companies are transforming real business operations using AI workflows, not just experimenting with flashy demos or proofs of concept. AI strategist Dustin Jensen breaks down what differentiates AI systems that scale from those that become expensive experiments. He explains why companies waste money when they “throw AI at a workf...

In today’s episode, we explore the Simplify to Scale approach — how companies can use AI, intelligent automation, and design thinking to remove operational friction, improve workflows, and unlock sustainable growth. Our guest, Anthony Franco , is a serial entrepreneur, AI strategist, and co-author of AI First Principles and The Wiser Method . He has launched and successfully exited six companies,...

What if drug testing didn’t need animals — or risky early-stage human trials? In today’s episode, we explore organ-on-a-chip technology , a breakthrough innovation that is transforming how drugs are developed, tested, and brought to market. These micro-sized devices — containing real living human cells — can accurately replicate the function of organs like the liver, lungs, brain, kidney, and inte...

In this episode, we explore one of the most disruptive advancements currently reshaping the pharmaceutical and biotech industry: AI-powered digital twins for clinical trials. Our guest, Aaron Smith, PhD — Founder and Head of Machine Learning at Unlearn. AI — breaks down how digital twins and generative AI are transforming drug development by enabling faster, smaller, and more efficient clinical tr...

What if artificial intelligence could detect throat cancer instantly — in real time — during a routine exam? In this groundbreaking episode, we speak with Marius Wellenstein, Founder and CEO of WSK Medical, the company behind the world’s first AI-powered endoscopic solution for real-time detection and classification of throat and head & neck cancers. Marius shares how his team developed a plug...

In this episode, we sit down with Dr. William Ho, President, CEO, and Co-Founder of IN8 Bio — a pioneering biotech company developing next-generation Gamma Delta T cell therapies for both solid and hematologic cancers. From Wall Street to the biotech lab, Dr. Ho shares his remarkable journey and how he’s leveraging artificial intelligence, data analytics, and computational biology to reshape cell...

In this episode, we explore the future of medicine beyond artificial intelligence with Joseph Geraci — mathematician, medical scientist, and quantum machine learning pioneer. While today’s AI breakthroughs and large language models (LLMs) have transformed diagnostics, data analysis, and drug discovery, quantum computing could completely redefine what’s possible in healthcare. Dr. Geraci breaks dow...

For decades, medical research has been built around male data — leaving women dangerously underrepresented in clinical trials, drug development, and symptom understanding. The result? Misdiagnoses, ineffective treatments, and life-threatening blind spots in women’s healthcare. In this episode, Sonja Rincon, CEO and founder of MenoTracker , reveals how artificial intelligence is finally beginning t...

What if your smartphone camera could detect your blood pressure, heart rate, stress levels, and early signs of disease — all in under a minute? In this groundbreaking episode, Remi Koscielny, CEO and Co-founder of Shen. AI , reveals how artificial intelligence is transforming everyday devices into powerful, non-invasive health monitoring tools. With over 5 billion smartphones in use worldwide — bu...

In this episode, we dive deep into how artificial intelligence (AI) is revolutionising digital marketing, from SEO optimisation to automated content creation, predictive analytics, and personalised campaigns. Our guest, Brandon Leibowitz, founder of SEO Optimisers , shares his expert insights on the future of AI-powered marketing, the best AI tools for SEO, and how to write effective ChatGPT promp...

In this episode, we dive into the escalating war between AI and cybercrime — where artificial intelligence is both the ultimate defense and the greatest vulnerability. Our guest, Grant McCracken, founder of Dark Horse Security , reveals how AI-driven cybersecurity, machine learning detection systems, and automated threat analysis are transforming how we fight cyber threats in real time. From...

Carlo Buckley, Founder and CEO of ID Health, joins the show to reveal how his company is transforming the future of personalised medicine through AI-driven, automated pharmaceutical manufacturing. For decades, personalised medicine has been limited by outdated manufacturing methods designed for mass production, not individual treatment. ID Health is changing that — pioneering a new way to produce...

In this episode, we explore how Explainable AI (XAI) is revolutionizing drug development, rare disease research, and precision medicine. Our guest, Frédéric Parmentier, Vice President of Data Science at Ariana Pharma , shares how their Explainable Artificial Intelligence (XAI) platform, KEM (Knowledge Extraction and Management), helps uncover critical biomarker signatures in small cohort clinical...

How can AI-powered sleep monitoring transform clinical trials, drug development, and healthcare at home? In this episode, Jonas Krauss, Vice President of Business at Sleepiz AG , joins us to explore how contactless AI monitoring is redefining the way researchers and clinicians collect and analyze sleep data, vital signs, and patient health trends. Using radar-based sensors and artificial intellige...

Can artificial intelligence really cut biomanufacturing timelines from years to hours ? The answer is yes — and it’s already happening. In this episode, we sit down with Justin Byers , founder and CEO of Axio BioPharma , to explore how AI-driven biomanufacturing is transforming the development of monoclonal antibodies, biologics, and vaccines. By leveraging machine learning, digital twins, and pre...

Over 90% of drugs fail during clinical development, costing billions and leaving patients without life-saving treatments. Why does the pharmaceutical industry face such a high drug development failure rate, and how can artificial intelligence change the story? In this episode, Vitalay Fomin , CEO and co-founder of Numenos AI, reveals how his team is rethinking clinical trials, biomarker discovery,...

As artificial intelligence transforms the way we create, invent, and innovate, it’s also forcing the legal world to face unprecedented challenges. In this episode, Dr. Don Simmonds , IP law expert and founder of IPITEC, dives deep into the future of intellectual property law in the age of AI . From AI-generated art and machine-written books to patent disputes over AI-created inventions, this conve...

In this cutting-edge episode, we explore how Edge AI is transforming drug discovery and revolutionising laboratory workflows, real-time molecular analysis, and protein folding predictions—all at the source of data collection. Joining us is Nuri Cankaya, Vice President of Commercial Marketing at Intel Corporation, and a renowned thought leader in AI and healthcare innovation. You'll discover how AI...

In this eye-opening episode, we sit down with Julia Komissarchik, CEO and Co-Founder of Glendor Inc., to explore the rapidly evolving intersection of AI in healthcare, medical data privacy, and patient data protection. With AI transforming clinical decision-making, diagnostics, and health research, traditional privacy approaches like de-identification are no longer sufficient. Julia, a seasoned ex...

Can AI truly revolutionize molecular biology if it’s built on unreliable data? In this game-changing episode, we speak with Dr. Jonathon O'Brien, founder and CEO of Golgi, about one of the most critical—and often overlooked—issues in biomedical AI: data reliability. With a background in biostatistics, proteomics, and machine learning, Dr. O’Brien shares how Golgi’s AI-powered computational platfor...

In this episode, we delve into the transformative power of real-world data (RWD) in modern healthcare. Our guest, Ted Sweetser , Vice President of Strategic Advertising and Partnerships at PurpleLab, shares expert insights on how real-world data is driving innovation in patient outcomes, market access, and public health strategy. From electronic health records (EHRs) and insurance claims data to w...

In this episode, former FDA leader and current SVP of Regulatory and Quality at Ariana Data Intelligence, Dr. Frederico Goodsaid, shares cutting-edge insights on how artificial intelligence (AI) is reshaping the landscape of drug discovery and development — particularly in the treatment of rare and orphan diseases. From breaking down the FDA's new guidance on AI to explaining why credibility now m...